内脏利什曼病合并HIV感染患者诊断和治疗研究进展  

Advances in diagnostics and treatment of visceral leishmaniasis co-infected with HIV

作　　者：何小庆 刘敏[1] 周璐[1] 陈耀凯[1] HE Xiao-qing;LIU Min;ZHOU Lu;CHEN Yao-kai(Chongqing public health medical center,Chongqing 400036,China)

机构地区：[1]重庆市公共卫生医疗救治中心,重庆400036

出　　处：《中国寄生虫学与寄生虫病杂志》2020年第2期245-249,共5页Chinese Journal of Parasitology and Parasitic Diseases

基　　金：“十三五”国家科技重大专项课题(No.2018ZX10302104,No.2017ZX10201101,No.2017ZX10202101);重庆市公共卫生医疗救治中心青年科研创新基金项目(No.2019QNKYXM08)。

摘　　要：内脏利什曼病是全球被忽视的传染病之一,危害严重。而利什曼原虫-人类免疫缺陷病毒(human immunodeficiency virus,HIV)合并感染对流行地区造成的威胁更甚。利什曼原虫与HIV存在相互作用,合并感染者在临床表现、诊断及治疗方面具有一定特殊性,其病死率及复发率均高于HIV阴性的内脏利什曼病患者。本文对利什曼原虫-HIV合并感染患者的临床表现、诊断和治疗进展进行综述。Visceral leishmaniasis is one of the most serious neglected tropical diseases in the world.The coinfection of Leishmania protozoa with human immunodeficiency virus(HIV)has emerged as a serious threat in endemic areas.Due to the interaction between Leishmania parasite and HIV,the coinfected patients display some special clinical manifestations,different diagnostic signs and treatment effects that cause higher mortality and recurrence rate than patients without HIV coinfection.The article aims to review the advances in the clinical manifestation,diagnostics and treatment of visceral leishmaniasis coinfected with HIV.

关 键 词：内脏利什曼病 人类免疫缺陷病毒 合并感染 诊断 治疗 

分 类 号：R531.6[医药卫生—内科学] R512.91[医药卫生—临床医学]